At the European Cancer Congress (ECC) 2015, Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, discusses BIRCH, a phase 2, single-arm clinical trial of atezolizumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, as first-line or subsequent therapy for patients with locally advanced or metastatic PD-L1-selected non-small cell lung cancer.

свернуть